Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial

Anders Jorsal; Caroline Kistorp; Pernille Holmager; Rasmus Stilling Tougaard; Roni R. Nielsen; Anja Hänselmann; Brian Nilsson; Jacob Eifer Møller; Jakob Hjort; Jon Rasmussen; Trine Welløv Boesgaard; Morten Schou; Lars Videbæk; Ida Gustafsson; Allan Flyvbjerg; Henrik Wiggers; Lise Tarnow

doi:10.1002/ejhf.657

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial

Anders Jorsal, Caroline Kistorp, Pernille Holmager, Rasmus Stilling Tougaard, Roni R. Nielsen, Anja Hänselmann, Brian Nilsson, Jacob Eifer Møller, Jakob Hjort, Jon Rasmussen, Trine Welløv Boesgaard, Morten Schou, Lars Videbæk, Ida Gustafsson, Allan Flyvbjerg, Henrik Wiggers, Lise Tarnow

186 Citations (Scopus)

Abstract

Aims: To determine the effect of the glucagon-like peptide-1 analogue liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes. Methods and results: LIVE was an investigator-initiated, randomised, double-blinded, placebo-controlled multicentre trial. Patients (n = 241) with reduced left ventricular ejection fraction (LVEF ≤45%) were recruited (February 2012 to August 2015). Patients were clinically stable and on optimal heart failure treatment. Intervention was liraglutide 1.8 mg once daily or matching placebo for 24 weeks. The LVEF was similar at baseline in the liraglutide and the placebo group (33.7 ± 7.6% vs. 35.4 ± 9.4%). Change in LVEF did not differ between the liraglutide and the placebo group; mean difference (95% confidence interval) was −0.8% (−2.1, 0.5; P = 0.24). Heart rate increased with liraglutide [mean difference: 7 b.p.m. (5, 9), P < 0.0001]. Serious cardiac events were seen in 12 (10%) patients treated with liraglutide compared with 3 (3%) patients in the placebo group (P = 0.04). Conclusion: Liraglutide did not affect left ventricular systolic function compared with placebo in stable chronic heart failure patients with and without diabetes. Treatment with liraglutide was associated with an increase in heart rate and more serious cardiac adverse events, and this raises some concern with respect to the use of liraglutide in patients with chronic heart failure and reduced left ventricular function. More data on the safety of liraglutide in different subgroups of heart failure patients are needed.

Original language	English
Journal	European Journal of Heart Failure
Volume	19
Issue number	1
Pages (from-to)	69-77
Number of pages	9
ISSN	1388-9842
DOIs	https://doi.org/10.1002/ejhf.657
Publication status	Published - 1 Jan 2017

Keywords

Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ejhf.657

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.657

Fingerprint

Dive into the research topics of 'Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this

Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R. S., Nielsen, R. R., Hänselmann, A., Nilsson, B., Møller, J. E., Hjort, J., Rasmussen, J., Boesgaard, T. W., Schou, M., Videbæk, L., Gustafsson, I., Flyvbjerg, A., Wiggers, H., & Tarnow, L. (2017). Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. European Journal of Heart Failure, 19(1), 69-77. https://doi.org/10.1002/ejhf.657

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. / Jorsal, Anders; Kistorp, Caroline; Holmager, Pernille et al.

In: European Journal of Heart Failure, Vol. 19, No. 1, 01.01.2017, p. 69-77.

Research output: Contribution to journal › Journal article › Research › peer-review

Jorsal, A, Kistorp, C, Holmager, P, Tougaard, RS, Nielsen, RR, Hänselmann, A, Nilsson, B, Møller, JE, Hjort, J, Rasmussen, J, Boesgaard, TW, Schou, M, Videbæk, L, Gustafsson, I, Flyvbjerg, A, Wiggers, H & Tarnow, L 2017, 'Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial', European Journal of Heart Failure, vol. 19, no. 1, pp. 69-77. https://doi.org/10.1002/ejhf.657

Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen RR, Hänselmann A et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. European Journal of Heart Failure. 2017 Jan 1;19(1):69-77. doi: 10.1002/ejhf.657

@article{68966991739f415b9507e27f6a19484c,

title = "Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial",

abstract = "Aims: To determine the effect of the glucagon-like peptide-1 analogue liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes. Methods and results: LIVE was an investigator-initiated, randomised, double-blinded, placebo-controlled multicentre trial. Patients (n = 241) with reduced left ventricular ejection fraction (LVEF ≤45%) were recruited (February 2012 to August 2015). Patients were clinically stable and on optimal heart failure treatment. Intervention was liraglutide 1.8 mg once daily or matching placebo for 24 weeks. The LVEF was similar at baseline in the liraglutide and the placebo group (33.7 ± 7.6% vs. 35.4 ± 9.4%). Change in LVEF did not differ between the liraglutide and the placebo group; mean difference (95% confidence interval) was −0.8% (−2.1, 0.5; P = 0.24). Heart rate increased with liraglutide [mean difference: 7 b.p.m. (5, 9), P < 0.0001]. Serious cardiac events were seen in 12 (10%) patients treated with liraglutide compared with 3 (3%) patients in the placebo group (P = 0.04). Conclusion: Liraglutide did not affect left ventricular systolic function compared with placebo in stable chronic heart failure patients with and without diabetes. Treatment with liraglutide was associated with an increase in heart rate and more serious cardiac adverse events, and this raises some concern with respect to the use of liraglutide in patients with chronic heart failure and reduced left ventricular function. More data on the safety of liraglutide in different subgroups of heart failure patients are needed.",

keywords = "Journal Article",

author = "Anders Jorsal and Caroline Kistorp and Pernille Holmager and Tougaard, {Rasmus Stilling} and Nielsen, {Roni R.} and Anja H{\"a}nselmann and Brian Nilsson and M{\o}ller, {Jacob Eifer} and Jakob Hjort and Jon Rasmussen and Boesgaard, {Trine Well{\o}v} and Morten Schou and Lars Videb{\ae}k and Ida Gustafsson and Allan Flyvbjerg and Henrik Wiggers and Lise Tarnow",

note = "{\textcopyright} 2016 The Authors. European Journal of Heart Failure {\textcopyright} 2016 European Society of Cardiology.",

year = "2017",

month = jan,

day = "1",

doi = "10.1002/ejhf.657",

language = "English",

volume = "19",

pages = "69--77",

journal = "European Journal of Heart Failure, Supplement",

issn = "1567-4215",

publisher = "JohnWiley & Sons Ltd",

number = "1",

}

TY - JOUR

T1 - Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial

AU - Jorsal, Anders

AU - Kistorp, Caroline

AU - Holmager, Pernille

AU - Tougaard, Rasmus Stilling

AU - Nielsen, Roni R.

AU - Hänselmann, Anja

AU - Nilsson, Brian

AU - Møller, Jacob Eifer

AU - Hjort, Jakob

AU - Rasmussen, Jon

AU - Boesgaard, Trine Welløv

AU - Schou, Morten

AU - Videbæk, Lars

AU - Gustafsson, Ida

AU - Flyvbjerg, Allan

AU - Wiggers, Henrik

AU - Tarnow, Lise

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Aims: To determine the effect of the glucagon-like peptide-1 analogue liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes. Methods and results: LIVE was an investigator-initiated, randomised, double-blinded, placebo-controlled multicentre trial. Patients (n = 241) with reduced left ventricular ejection fraction (LVEF ≤45%) were recruited (February 2012 to August 2015). Patients were clinically stable and on optimal heart failure treatment. Intervention was liraglutide 1.8 mg once daily or matching placebo for 24 weeks. The LVEF was similar at baseline in the liraglutide and the placebo group (33.7 ± 7.6% vs. 35.4 ± 9.4%). Change in LVEF did not differ between the liraglutide and the placebo group; mean difference (95% confidence interval) was −0.8% (−2.1, 0.5; P = 0.24). Heart rate increased with liraglutide [mean difference: 7 b.p.m. (5, 9), P < 0.0001]. Serious cardiac events were seen in 12 (10%) patients treated with liraglutide compared with 3 (3%) patients in the placebo group (P = 0.04). Conclusion: Liraglutide did not affect left ventricular systolic function compared with placebo in stable chronic heart failure patients with and without diabetes. Treatment with liraglutide was associated with an increase in heart rate and more serious cardiac adverse events, and this raises some concern with respect to the use of liraglutide in patients with chronic heart failure and reduced left ventricular function. More data on the safety of liraglutide in different subgroups of heart failure patients are needed.

AB - Aims: To determine the effect of the glucagon-like peptide-1 analogue liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes. Methods and results: LIVE was an investigator-initiated, randomised, double-blinded, placebo-controlled multicentre trial. Patients (n = 241) with reduced left ventricular ejection fraction (LVEF ≤45%) were recruited (February 2012 to August 2015). Patients were clinically stable and on optimal heart failure treatment. Intervention was liraglutide 1.8 mg once daily or matching placebo for 24 weeks. The LVEF was similar at baseline in the liraglutide and the placebo group (33.7 ± 7.6% vs. 35.4 ± 9.4%). Change in LVEF did not differ between the liraglutide and the placebo group; mean difference (95% confidence interval) was −0.8% (−2.1, 0.5; P = 0.24). Heart rate increased with liraglutide [mean difference: 7 b.p.m. (5, 9), P < 0.0001]. Serious cardiac events were seen in 12 (10%) patients treated with liraglutide compared with 3 (3%) patients in the placebo group (P = 0.04). Conclusion: Liraglutide did not affect left ventricular systolic function compared with placebo in stable chronic heart failure patients with and without diabetes. Treatment with liraglutide was associated with an increase in heart rate and more serious cardiac adverse events, and this raises some concern with respect to the use of liraglutide in patients with chronic heart failure and reduced left ventricular function. More data on the safety of liraglutide in different subgroups of heart failure patients are needed.

KW - Journal Article

U2 - 10.1002/ejhf.657

DO - 10.1002/ejhf.657

M3 - Journal article

C2 - 27790809

SN - 1567-4215

VL - 19

SP - 69

EP - 77

JO - European Journal of Heart Failure, Supplement

JF - European Journal of Heart Failure, Supplement

IS - 1

ER -